Target intelligence / Profile preview

Transcription factor EB (TFEB) (TFEB)

Target
TFEB
Molecular classification
Transcription factor, Basic helix-loop-helix leucine zipper protein, MiT/TFE family
01

Overview

Transcription factor EB (TFEB) is a master regulator of the autophagy-lysosome pathway and a member of the MiT/TFE family of basic helix-loop-helix leucine zipper transcription factors (UniProt P19484). It orchestrates the expression of the Coordinated Lysosomal Expression and Regulation (CLEAR) gene network, which is critical for lysosomal biogenesis, autophagosome formation, and cellular clearance (Settembre et al., 2011, Nature). Under normal conditions, TFEB is phosphorylated by kinases such as mTORC1 and ERK2, which promotes its sequestration in the cytoplasm via 14-3-3 protein binding (Napolitano & Ballabio, 2016, Journal of Cell Science). Upon stress, nutrient deprivation, or lysosomal dysfunction, TFEB is dephosphorylated (often by calcineurin), allowing it to translocate to the nucleus and activate transcription (Medina et al., 2015, Nature). TFEB is a significant therapeutic target for neurodegenerative diseases like Alzheimer's and Parkinson's, as well as lysosomal storage disorders, where its activation can clear toxic protein aggregates (Decressac et al., 2013, PNAS). However, its dysregulation is also implicated in certain cancers, particularly renal cell carcinomas and melanomas, where it acts as an oncogene, suggesting that both activation and inhibition are viable therapeutic strategies depending on the disease context (Palmieri et al., 2011, EMBO Journal).

Other names
TCFEBBHLHE35Alpha-TFEBTranscription factor EB mRNABasic helix-loop-helix domain-containing protein 35
02

Mechanism of action

Activation of TFEB through dephosphorylation and nuclear translocation, leading to the upregulation of the CLEAR (Coordinated Lysosomal Expression and Regulation) gene network for enhanced lysosomal biogenesis and autophagic flux.

03

Biological functions

Lysosomal biogenesisAutophagyLipid metabolismEnergy homeostasisImmune responseCellular clearance
04

Disease associations

Neurodegenerative diseaseLysosomal storage disorderCancerMetabolic diseaseCardiovascular disease
05

Safety considerations

Potential oncogenic activity in renal cell carcinoma and melanomaDisruption of systemic metabolic homeostasisRisk of excessive autophagic cell deathOff-target effects of RNA-targeting modalities
06

Interacting drugs

Trehalose

9 more in the full profile.

07

Biomarkers

Nuclear TFEB localizationLAMP1 expressionLC3-II/I ratioSQSTM1/p62 protein levelsCathepsin D (CTSD) expression

Beyond the preview

Go deeper on Transcription factor EB (TFEB) (TFEB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcription factor EB (TFEB) (TFEB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call